CytoDyn Reports 86% Median ctDNA Reduction at Week 2 in Phase 2 Colorectal Cancer Trial

PUBT · 1d ago
CytoDyn Reports 86% Median ctDNA Reduction at Week 2 in Phase 2 Colorectal Cancer Trial
  • CytoDyn presented updated Phase 2 CLOVER results in metastatic colorectal cancer at ESMO in Madrid on Oct. 25, 2026.
  • The study enrolled 66 patients across seven sites between June 2025 and May 2026.
  • Patients received leronlimab with trifluridine/tipiracil and bevacizumab.
  • The combination produced deeper reductions in blood-based tumor DNA than the regimens without leronlimab.
  • Available safety data showed no leronlimab-related treatment discontinuations, serious toxicities limiting dosing or adverse events above moderate severity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260830PRIMZONEFULLFEED9852667) on October 26, 2026, and is solely responsible for the information contained therein.